RLRachel A. Jones Lipinski

Rachel A. Jones Lipinski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rachel A. Jones Lipinski has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Role of SIRT3 in the regulation of Gadd45α expression and DNA repair in β-cells

    by Aaron Naatz, Kelsey S. Bohl, Rachel A. Jones Lipinski, Joshua A. Nord, Alyssa L. Gehant, Polly A. Hansen, Brian C. Smith, John A. Corbett


  • Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types

    by Rachel A. Jones Lipinski, Jennifer S. Stancill, Raymundo Nuñez, Sarah L. Wynia-Smith, Daniel J. Sprague, Joshua A. Nord, Amir Bird, John A. Corbett, Brian C. Smith

    Inhibition of BET bromodomains is a novel potential strategy to prevent and treat diabetes mellitus. However, BET inhibitors have negative side effects. We synthesized a BET inhibitor expected to exploit the high zinc concentration in β cells to accumulate in β cells. We show our inhibitor targeted pancreatic endocrine cells; however, it was less effective in immune cells. A control inhibitor showed the opposite effect. These findings help us understand how to target specific cells in diabetes treatment.


  • Molecular docking‐guided synthesis of NSAID–glucosamine bioconjugates and their evaluation as COX‐1/COX‐2 inhibitors with potentially reduced gastric toxicity

    by Rachel A. Jones Lipinski, Yann Thillier, Christophe Morisseau, Christopher S. Sebastiano, Brian C. Smith, C. Dennis Hall, Alan R. Katritzky

    Non‐steroidal anti‐inflammatory drugs (NSAIDs) are a powerful class of inhibitors targeting two isoforms of the family of cyclooxygenase enzymes (COX‐1 and COX‐2). While NSAIDs are widely used in the management of pain, in particular as a treatment for osteo‐ and rheumatoid arthritis, their long‐term use has been associated with numerous on‐ and off‐target effects. As the carboxylic acid moiety present in common NSAIDs is responsible for some of their adverse effects, but is not required for their anti‐inflammatory activity, we sought to mask this group through direct coupling to glucosamine, which is thought to prevent cartilage degradation. We report herein the conjugation of commonly prescribed NSAIDs to glucosamine hydrochloride and the use of molecular docking to show that addition of the carbohydrate moiety to the parent NSAID can enhance binding in the active site of COX‐2. In a preliminary, in vitro screening assay, the diclofenac‐glucosamine bioconjugate exhibited 10‐fold greater activity toward COX‐2, making it an ideal candidate for future in vivo studies. Furthermore, in an intriguing result, we observed that the mefenamic acid‐glucosamine bioconjugate displayed enhanced activity toward COX‐1 rather than COX‐2.


  • Open Access

    SurfaceGenie: a web-based application for prioritizing cell-type-specific marker candidates

    by Matthew Waas, Shana T Snarrenberg, Jack Littrell, Rachel A Jones Lipinski, Polly A Hansen, John A Corbett, Rebekah L Gundry

    Cell-type-specific surface proteins can be exploited as valuable markers for a range of applications including immunophenotyping live cells, targeted drug delivery and in vivo imaging. Despite their utility and relevance, the unique combination of molecules present at the cell surface are not yet described for most cell types. A significant challenge in analyzing ‘omic’ discovery datasets is the selection of candidate markers that are most applicable for downstream applications. Here, we developed GenieScore, a prioritization metric that integrates a consensus-based prediction of cell surface localization with user-input data to rank-order candidate cell-type-specific surface markers. In this report, we demonstrate the utility of GenieScore for analyzing human and rodent data from proteomic and transcriptomic experiments in the areas of cancer, stem cell and islet biology. We also demonstrate that permutations of GenieScore, termed IsoGenieScore and OmniGenieScore, can efficiently prioritize co-expressed and intracellular cell-type-specific markers, respectively. Calculation of GenieScores and lookup of SPC scores is made freely accessible via the SurfaceGenie web application: www.cellsurfer.net/surfacegenie. Rebekah.gundry@unmc.edu Supplementary data are available at Bioinformatics online.


  • Open Access

    SurfaceGenie: a web-based application for prioritizing cell-type specific marker candidates

    by Matthew Waas, Shana T. Snarrenberg, Jack Littrell, Rachel A. Jones Lipinski, Polly A. Hansen, John A. Corbett, Rebekah L. Gundry

    Motivation: Cell-type specific surface proteins can be exploited as valuable markers for a range of applications including immunophenotyping live cells, targeted drug delivery, and in vivo imaging. Despite their utility and relevance, the unique combination of molecules present at the cell surface are not yet described for most cell types. A significant challenge in analyzing ‘omic’ discovery datasets is the selection of candidate markers that are most applicable for downstream applications. Results: Here, we developed GenieScore , a prioritization metric that integrates a consensus-based prediction of cell surface localization with user-input data to rank-order candidate cell-type specific surface markers. In this report, we demonstrate the utility of GenieScore for analyzing human and rodent data from proteomic and transcriptomic experiments in the areas of cancer, stem cell, and islet biology. We also demonstrate that permutations of GenieScore , termed IsoGenieScore and OmniGenieScore, can efficiently prioritize co-expressed and intracellular cell-type specific markers, respectively. Availability and Implementation: Calculation of GenieScores and lookup of SPC scores is made freely accessible via the SurfaceGenie web-application: www.cellsurfer.net/surfacegenie .


  • SP2: Rapid and Automatable Contaminant Removal from Peptide Samples for Proteomic Analyses

    by Matthew Waas, Michaela Pereckas, Rachel A. Jones Lipinski, Christopher Ashwood, Rebekah L. Gundry

    Peptide cleanup is essential for the removal of contaminating substances that may be introduced during sample preparation steps in bottom-up proteomic workflows. Recent studies have described benefits of carboxylate-modified paramagnetic particles over traditional reversed-phase methods for detergent and polymer removal, but challenges with reproducibility have limited the widespread implementation of this approach among laboratories. To overcome these challenges, the current study systematically evaluated key experimental parameters regarding the use of carboxylate-modified paramagnetic particles and determined those that are critical for maximum performance and peptide recovery and those for which the protocol is tolerant to deviation. These results supported the development of a detailed, easy-to-use standard operating protocol, termed SP2, which can be applied to remove detergents and polymers from peptide samples while concentrating the sample in solvent that is directly compatible with typical LC–MS workflows. We demonstrate that SP2 can be applied to phosphopeptides and glycopeptides and that the approach is compatible with robotic liquid handling for automated sample processing. Altogether, the results of this study and accompanying detailed operating protocols for both manual and automated processing are expected to facilitate reproducible implementation of SP2 for various proteomics applications and will especially benefit core or shared resource facilities where unknown or unexpected contaminants may be particularly problematic.


  • Discovery and characterization of halogenated xanthene inhibitors of DUSP5 as potential photodynamic therapeutics

    by Robert D. Bongard, Michael Lepley, Adam Gastonguay, Raulia R. Syrlybaeva, Marat R. Talipov, Rachel A. Jones Lipinski, Noah R. Leigh, Jaladhi Brahmbhatt, Raman Kutty, Rajendra Rathore, et al.


  • Open Access

    Biosynthetic tailoring of existing ascaroside pheromones alters their biological function in C. elegans

    by Yue Zhou, Yuting Wang, Xinxing Zhang, Subhradeep Bhar, Rachel A Jones Lipinski, Jungsoo Han, Likui Feng, Rebecca A Butcher

    Caenorhabditis elegans produces ascaroside pheromones to control its development and behavior. Even minor structural differences in the ascarosides have dramatic consequences for their biological activities. Here, we identify a mechanism that enables C. elegans to dynamically tailor the fatty-acid side chains of the indole-3-carbonyl (IC)-modified ascarosides it has produced. In response to starvation, C. elegans uses the peroxisomal acyl-CoA synthetase ACS-7 to activate the side chains of medium-chain IC-ascarosides for β-oxidation involving the acyl-CoA oxidases ACOX-1.1 and ACOX-3. This pathway rapidly converts a favorable ascaroside pheromone that induces aggregation to an unfavorable one that induces the stress-resistant dauer larval stage. Thus, the pathway allows the worm to respond to changing environmental conditions and alter its chemical message without having to synthesize new ascarosides de novo. We establish a new model for biosynthesis of the IC-ascarosides in which side-chain β-oxidation is critical for controlling the type of IC-ascarosides produced.


  • Acyl-CoA Oxidases Fine-Tune the Production of Ascaroside Pheromones with Specific Side Chain Lengths

    by Xinxing Zhang, Yuting Wang, David H. Perez, Rachel A. Jones Lipinski, Rebecca A. Butcher

    Caenorhabditis elegans produces a complex mixture of ascaroside pheromones to control its development and behavior. Acyl-CoA oxidases, which participate in β-oxidation cycles that shorten the side chains of the ascarosides, regulate the mixture of pheromones produced. Here, we use CRISPR-Cas9 to make specific nonsense and missense mutations in acox genes and determine the effect of these mutations on ascaroside production in vivo. Ascaroside production in acox-1.1 deletion and nonsense strains, as well as a strain with a missense mutation in a catalytic residue, confirms the central importance of ACOX-1.1 in ascaroside biosynthesis and suggests that ACOX-1.1 functions in part by facilitating the activity of other acyl-CoA oxidases. Ascaroside production in an acox-1.1 strain with a missense mutation in an ATP-binding site at the ACOX-1.1 dimer interface suggests that ATP binding is important for the enzyme to function in ascaroside biosynthesis in vivo. Ascaroside production in strains with deletion, nonsense, and missense mutations in other acox genes demonstrates that ACOX-1.1 works with ACOX-1.3 in processing ascarosides with 7-carbon side chains, ACOX-1.4 in processing ascarosides with 9- and 11-carbon side chains, and ACOX-3 in processing ascarosides with 13- and 15-carbon side chains. It also shows that ACOX-1.2, but not ACOX-1.1, processes ascarosides with 5-carbon ω-side chains. By modeling the ACOX structures, we uncover characteristics of the enzyme active sites that govern substrate preferences. Our work demonstrates the role of specific acyl-CoA oxidases in controlling the length of ascaroside side chains and thus in determining the mixture of pheromones produced by C. elegans.


  • Spirooxindoles as Potential Pharmacophores

    by Siva S. Panda, Rachel A. Jones, Praveen Bachawala, Prabhu P. Mohapatra

    Objective: The spirooxindole heterocyclic scaffold is found in many natural products and has been identified as an important bioactive agent. Background: Over the past few decades, various spirooxindole-containing compounds have been reported to possess biological properties and hence found in the structure of many synthetic pharmaceuticals. This mini-review describes the most promising examples of this class of compounds possessing biological activity including anticancer, anti-inflammatory, and antimicrobial activities. Conclusion: The current review focuses on the biological activity of compounds containing the spirooxindole scaffold.